Search
ASCO 2026: Ascentage Pharma is currently in nine registration trials, four of which are global studies intended for FDA and EMA filings. The founder, Dajun Yang, discusses this work, and ASCO data
He describes how Ascentage, which is already commercializing two medicines in China, has been working on its global programs. Plus, an overview of ASCO data (3 oral presentations and 3 posters) on the BCR-ABL inhibitor olverembatinib, Bcl-2 inhibitor lisaftoclax, and MDM2-p53 inhibitor alrizomadlin (APG-115).
May 31
ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftoclax, which was recently approved in China and is in multiple global registration studies
The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, an update on global studies of the BCR-ABL/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor. Coverage brought to you by
Dec 9, 2025
EHA 2025: The CEO of Ascentage Pharma, which had its U.S. IPO earlier this year, introduces us to the company and discusses BCR-ABL, Bcl-2, and EED targeting programs
Dajun Yang shares the history of Ascentage, talks about what makes the BCR-ABL program, which Takeda took an option on, a...
Jun 14, 2025
.png){kind=logo}
